Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) [Yahoo! Finance]
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.